The Venture Codex

Led · Series A · Dec 2025

Evidium is a San Francisco–based health-tech company building a computational medical knowledge platform that converts medical evidence into precision intelligence. Its technology produces traceable, transparent insights that help clinicians, insurers, risk-bearing organizations, and provider networks understand patient journeys, predict medical and cost trajectories, and improve outcomes. Current products include quality insights for care teams, probabilistic forecasting tools for payers, and advanced clinical and cost modeling solutions that map condition-level care pathways. The company’s precision-first approach allows experts to review the logic behind every prediction, augmenting generative AI with clinically grounded reasoning. With fresh capital, Evidium will deepen its clinical modeling capabilities, extend its product roadmap for life-sciences and health-plan users, and scale commercial operations. It is preparing strategic hires in AI research engineering, clinical science, and business development to meet rising demand across the healthcare ecosystem. Financially, Evidium has just closed a $22 million Series A round to support these growth initiatives.

Participated · Series A · Jun 2025

HOPPR offers a purpose-built platform for developers and PACS vendors to fine-tune and deploy foundation models for medical imaging with secure tooling, curated datasets, and traceable data provenance. The platform emphasizes quality management, secure development pipelines, and support for marketing authorization to help move models from concept to clinical deployment. HOPPR enables users to use their own data or HOPPR’s expertly curated datasets to develop high-performing, clinically ready AI applications. The company positions itself as an alternative to marketplaces by focusing on model refinement, validation, and clinical readiness rather than prebuilt apps. With an oversubscribed Series A, HOPPR plans to accelerate platform development, scale operations, expand its foundation model capabilities, and grow its engineering, AI, and compliance teams. The company frames these efforts as enabling improved diagnostic workflows and better patient care globally.

Participated · Equity · Sep 2024

Zing Health offers managed-care Medicare Advantage plans that include supplemental benefits and access to a broad network of provider partners. Each member receives personalized care tailored to health conditions and social needs, enabled by product design, technology, and value-based care delivery. The company emphasizes integrated plans focused on chronic special needs. Zing Health intends to use the new proceeds to expand those integrated, chronic special needs focused plans to more beneficiaries and to further integrate its member experience with high-quality care providers. The business is led by CEO Andrew Clifton and was co-founded in 2019 by Dr. Eric Whitaker and Garfield Collins alongside Health 2047. The company is based in Chicago, Illinois.

Participated · Series A · May 2024

Phenomix Sciences is a Menlo Park, Calif.-based precision medicine biotechnology company that applies data intelligence to obesity treatment through its MyPhenome™ test. MyPhenome equips physicians to tailor treatment plans — including lifestyle and diet intervention, medication, and procedures — by identifying obesity phenotypes such as Hungry Gut, Hungry Brain, and Emotional Hunger. The company raised $7.8M, comprising $5.5M in Series A funding from new investors DexCom and Labcorp (and existing investors including Health2047) plus a $2.3M Phase II SBIR grant from the NIH. Phenomix will use the capital to accelerate commercialization and adoption of MyPhenome in the obesity specialist market and the wider industry, develop and launch additional phenotyping tests, continue supporting clinical studies, and patent novel insights. The NIH SBIR grant specifically funds a prospective study to further validate MyPhenome's accuracy in predicting obesity treatment response. The company also plans to further strategic relationships with pharmaceutical companies and health care providers.

Led · Seed · Jan 2024

HEAL Security builds a cognitive cybersecurity intelligence platform custom-designed for the healthcare sector and launched out of stealth with its flagship HEAL Security Desktop. The platform consolidates data, insights, and assessments of the global healthcare cybersecurity landscape into a dashboard that enables customers to evaluate and act on cyber threats and risks. The company positions itself as the sole cyber intelligence entity exclusively devoted to healthcare and was founded in 2021 in response to rising attacks on hospitals, health systems, and electronic health records. HEAL emphasizes real-time, actionable insights to help providers proactively protect business-critical data, systems, and continuity of care. Financially, HEAL launched with a pre-seed backing totaling $4.6 million, including a $2.3 million investment from Health2047.